Study identifier:9393IL/0028
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomized Clinical Trial Comparing Goserelin Acetate (ZOLADEX tm) 3.6-mg Depot and Goserelin Acetate (Zoladex) 10.8-MG Depot in Subjects with Prostate Cancer for Whom Hormonal Therapy is Indicated
prostate cancer
Phase 4
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|